Clinical Trial Update: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS [Phase 3]

View source ↗

Summary

A completed Phase 3 open-label trial comparing ofatumumab 20 mg with a first-line disease-modifying therapy in relapsing multiple sclerosis to evaluate efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED